Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Mind Medicine (MindMed) Inc
Intangible Assets
Mind Medicine (MindMed) Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Intangible Assets
$4.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-15%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Intangible Assets
CA$76.2m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
3%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Intangible Assets
CA$59.2m
|
CAGR 3-Years
24%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Intangible Assets
$8.9m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
22%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Intangible Assets
CA$377.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
19%
|
CAGR 10-Years
61%
|
|
Mind Medicine (MindMed) Inc
Glance View
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.
